Christy Santhosh

1 week ago | dagenspharma.dk | Chandni Shah |Mariam E Sunny |Christy Santhosh

Moderna COVID vaccine approved for those 12-64 with risk factorsModerna expects mNEXSPIKE to be ready for 2025-2026 seasonVaccine easier to distribute in developing countriesMay 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's (MRNA.O), opens new tab next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements.

2 weeks ago | zawya.com | Puyaan Singh |Christy Santhosh

U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period should target newer strains of the JN.1 variant. COVID vaccine makers are seeing increased regulatory scrutiny under the new FDA leadership, facing tighter requirements for their shots that could increase expenses.

2 weeks ago | marketscreener.com | Puyaan Singh |Christy Santhosh

Published on 05/22/2025 at 14:56, updated on 05/23/2025 at 10:55 (Reuters) - U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period should target newer strains of the JN.1 variant. COVID vaccine makers are seeing increased regulatory scrutiny under the new FDA leadership, facing tighter requirements for their shots that could increase expenses.

2 weeks ago | reuters.com | Christy Santhosh |Puyaan Singh

May 22 (Reuters) - The U.S. Food and Drug Administration's advisory panel is set to vote on Thursday to recommend whether COVID-19 vaccines for the 2025-2026 immunization campaign should target strains of the virus descending from the JN.1 variant. According to the Centers for Disease Control and Prevention, the LP.8.1 strain - a subvariant of the previously recommended JN.1 strain - accounted for 70% of total cases in the U.S. over a two-week period ended May 10. Sign up here.

2 weeks ago | gazette.com | Puyaan Singh |Christy Santhosh

By Puyaan Singh and Christy Santhosh(Reuters) - U.S. Food and Drug Administration advisers unanimously recommended on Thursday that COVID-19 vaccines for the 2025-26 period should target newer strains of the JN.1 variant. COVID vaccine makers are seeing increased regulatory scrutiny under the new FDA leadership, facing tighter requirements for their shots that could increase expenses.